Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Touchstne Inov 3 1/33P (IVO)

Date Time Source Announcement
13 Nov 2017 7:01 am
RNS
Board changes following cancellation of admission
  7:00 am
RNS
Notice of cancellation of admission to AIM
27 Oct 2017 10:54 am
RNS
Posting of Annual Report
18 Oct 2017 9:38 am
RNS
Updated recommendation by Touchstone Innovations
17 Oct 2017 9:10 am
RNS
Grant of share options
04 Oct 2017 7:00 am
RNS
Touchstone invests �1.4m in Featurespace round
13 Sep 2017 7:00 am
RNS
Final Results
12 Sep 2017 7:00 am
RNS
Touchstone commits funds to Ieso Digital Health
01 Aug 2017 7:00 am
RNS
Publication of Response Circular
18 Jul 2017 12:16 pm
RNS
Posting of offer document by IP Group plc
17 Jul 2017 7:00 am
RNS
Touchstone invests in WaveOptics
14 Jul 2017 7:00 am
RNS
Trading update - NAV increased to �502 million
28 Jun 2017 7:00 am
RNS
Chairman's letter to shareholders
26 Jun 2017 7:00 am
RNS
Innovations invests �4.0m in Yoyo
21 Jun 2017 7:00 am
RNS
Innovations invests in Impression Technologies
20 Jun 2017 6:08 pm
RNS
Statement re offer by IP Group plc
19 Jun 2017 7:00 am
RNS
Commits �3.0 million investment in Concirrus
07 Jun 2017 11:48 am
RNS
Form 8 (OPD) (IP Group PLC)
  11:45 am
RNS
Form 8 (OPD) (Touchstone Innovations plc)
01 Jun 2017 7:00 am
RNS
Chairman's letter to shareholders
23 May 2017 10:33 am
RNS
Statement re Possible Offer
21 Apr 2017 11:21 am
RNS
Innovations invests �2.9m in Abzena placing
06 Apr 2017 7:00 am
RNS
Innovations provides seed funding for Cardian
31 Mar 2017 7:00 am
RNS
Half Yearly Report
20 Mar 2017 7:05 am
RNS
Innovations supports funding round in Pulmocide
16 Mar 2017 7:00 am
RNS
Innovations invests in Cell Medica funding round
14 Mar 2017 7:00 am
RNS
Innovations supports funding round in Resolver
06 Mar 2017 7:00 am
RNS
Innovations leads �12m funding round in Garrison
28 Feb 2017 11:11 am
RNS
Notice of Results
21 Feb 2017 7:03 am
RNS
Cell Medica granted FDA Fast Track designation
26 Jan 2017 2:00 pm
RNS
Directorate Change
05 Jan 2017 7:00 am
RNS
Change of name to Touchstone Innovations plc
04 Jan 2017 9:00 am
RNS
Appointment of Joint Broker
20 Dec 2016 12:03 pm
RNS
PsiOxus signs exclusive licence agreement with BMS
28 Nov 2016 7:02 am
RNS
Portfolio company TopiVert receives IND approval
23 Nov 2016 5:56 pm
RNS
Grant of share options
21 Nov 2016 12:53 pm
RNS
Result of AGM
28 Oct 2016 12:30 pm
RNS
Proposed change of name to Touchstone Innovations
  12:29 pm
RNS
Posting of Annual Report and Notice of AGM
24 Oct 2016 7:12 am
RNS
Veryan announces completion of subject enrolment
13 Oct 2016 7:00 am
RNS
Final Results
10 Oct 2016 1:02 pm
RNS
Crescendo Biologics sign collaboration with Takeda
06 Oct 2016 7:02 am
RNS
First patients dosed in TopiVert's Phase IIa study
03 Oct 2016 12:10 pm
RNS
Sale of Innovations portfolio company Permasense
21 Sep 2016 7:06 am
RNS
Innovations invests �5.1m in Artios Pharma Limited
14 Sep 2016 12:02 pm
RNS
Notice of Results
13 Sep 2016 4:08 pm
RNS
TR-1: Notification of major interest in shares
09 Sep 2016 1:15 pm
RNS
Holding(s) in Company
06 Sep 2016 4:17 pm
RNS
Edison issues update on Imperial Innovations (IVO)
05 Sep 2016 2:40 pm
RNS
Holding(s) in Company
24 Aug 2016 7:01 am
RNS
Cell Medica and UCL collaboration
12 Jul 2016 7:02 am
RNS
Cell Medica acquires Delenex Therapeutics
06 Jul 2016 7:00 am
RNS
Econic raises �5m to develop novel catalyst tech
30 Jun 2016 12:11 pm
RNS
PsiOxus and Bristol-Myers Squibb collaboration
28 Jun 2016 7:00 am
RNS
Storm Therapeutics raises �12m
21 Jun 2016 4:35 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
Director's share purchase
20 Jun 2016 7:03 am
RNS
Circassia cat allergy Phase III study
17 Jun 2016 7:00 am
RNS
Cell Medica and Baylor College of Medicine partner
16 Jun 2016 10:44 am
RNS
Replacement Holding(s) in Company
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t